Stocks
Cellebrite DI Sees Price Target Cut by JPMorgan Chase & Co.
Cellebrite DI (NASDAQ:CLBT) received a revised price target of $16.00 from JPMorgan Chase & Co., down from $20.00, in a research report issued on Friday.
The brokerage maintained its 'overweight' rating on the stock and forecasted a potential upside of 45.79% from Cellebrite's current price of $10.97.
This move is part of several updates to Cellebrite's price targets, with DA Davidson decreasing its target to $15.00 and Needham & Company lowering theirs to $12.50 in recent days.